CN114105986A - 一种芳香稠环二酮类化合物及其制备方法与应用 - Google Patents
一种芳香稠环二酮类化合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN114105986A CN114105986A CN202111472410.2A CN202111472410A CN114105986A CN 114105986 A CN114105986 A CN 114105986A CN 202111472410 A CN202111472410 A CN 202111472410A CN 114105986 A CN114105986 A CN 114105986A
- Authority
- CN
- China
- Prior art keywords
- substituted
- unsubstituted
- compound
- formula
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 diketone compound Chemical class 0.000 title claims abstract description 62
- 125000003118 aryl group Chemical group 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 108
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 14
- 125000006643 (C2-C6) haloalkenyl group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 150000003254 radicals Chemical class 0.000 claims description 14
- 125000001624 naphthyl group Chemical group 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 229910004749 OS(O)2 Inorganic materials 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000005594 diketone group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 6
- 229940125842 Chitinase inhibitor Drugs 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 claims description 4
- 229910003827 NRaRb Inorganic materials 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- ANGDWNBGPBMQHW-UHFFFAOYSA-N methyl cyanoacetate Chemical compound COC(=O)CC#N ANGDWNBGPBMQHW-UHFFFAOYSA-N 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 3
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102000012286 Chitinases Human genes 0.000 abstract description 42
- 108010022172 Chitinases Proteins 0.000 abstract description 42
- 230000002401 inhibitory effect Effects 0.000 abstract description 22
- 241000282414 Homo sapiens Species 0.000 abstract description 13
- 241000346285 Ostrinia furnacalis Species 0.000 abstract description 11
- 241000607715 Serratia marcescens Species 0.000 abstract description 7
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 abstract description 5
- 241000244203 Caenorhabditis elegans Species 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 3
- 241001225321 Aspergillus fumigatus Species 0.000 abstract description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000007787 solid Substances 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 238000000967 suction filtration Methods 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 241000244206 Nematoda Species 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 235000001508 sulfur Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LPCQBTAOTIZGAE-UHFFFAOYSA-N 2h-pyrimidine-1-carboxamide Chemical compound NC(=O)N1CN=CC=C1 LPCQBTAOTIZGAE-UHFFFAOYSA-N 0.000 description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 2
- 102100037839 Acidic mammalian chitinase Human genes 0.000 description 2
- 101710178876 Acidic mammalian chitinase Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- FKTXDTWDCPTPHK-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical group FC(F)(F)[C](F)C(F)(F)F FKTXDTWDCPTPHK-UHFFFAOYSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- KNBKMDSCOIGXEO-UHFFFAOYSA-N 2,3-dihydroimidazo[1,2-a]pyridine Chemical compound C1=CC=C[C]2[N]CCN21 KNBKMDSCOIGXEO-UHFFFAOYSA-N 0.000 description 1
- MZAZSAHKQBGEMA-UHFFFAOYSA-N 2,6,7,8-tetrahydrocyclopenta[2,3]thieno[2,4-d]pyrimidin-1-one Chemical compound OC1=NC=NC2=C1C(CCC1)=C1S2 MZAZSAHKQBGEMA-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- GRPNAYGQWRHKDA-UHFFFAOYSA-N 2-chloro-9-methyl-4-oxopyrido[1,2-a]pyrimidine-3-carbaldehyde Chemical compound CC1=CC=CN2C1=NC(Cl)=C(C=O)C2=O GRPNAYGQWRHKDA-UHFFFAOYSA-N 0.000 description 1
- SYFMQBDZEJECPU-UHFFFAOYSA-N 2-cyano-n-(pyridin-3-ylmethyl)acetamide Chemical compound N#CCC(=O)NCC1=CC=CN=C1 SYFMQBDZEJECPU-UHFFFAOYSA-N 0.000 description 1
- KZDHTEHBHTWMIC-UHFFFAOYSA-N 2-hydroxy-9-methylpyrido[1,2-a]pyrimidin-4-one Chemical compound CC1=CC=CN2C1=NC(O)=CC2=O KZDHTEHBHTWMIC-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- GONWIOACWVKSCD-UHFFFAOYSA-N 2h-pyrimidine-1-carbaldehyde Chemical compound O=CN1CN=CC=C1 GONWIOACWVKSCD-UHFFFAOYSA-N 0.000 description 1
- RGDQRXPEZUNWHX-UHFFFAOYSA-N 3-methylpyridin-2-amine Chemical compound CC1=CC=CN=C1N RGDQRXPEZUNWHX-UHFFFAOYSA-N 0.000 description 1
- CBKDCOKSXCTDAA-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1-benzothiophene Chemical compound C1CCCC2=C1C=CS2 CBKDCOKSXCTDAA-UHFFFAOYSA-N 0.000 description 1
- TVMQVYSEIHVKRI-UHFFFAOYSA-N 4h-indeno[2,1-b]thiophene Chemical compound C1C2=CC=CC=C2C2=C1SC=C2 TVMQVYSEIHVKRI-UHFFFAOYSA-N 0.000 description 1
- ZDONPXIOHABCEA-UHFFFAOYSA-N 7,8-dihydro-6h-cyclopenta[4,5]thieno[1,2-b]pyrimidine Chemical compound S1C2=NC=NC=C2C2=C1CCC2 ZDONPXIOHABCEA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- CHVBUQHMBCYXDS-UHFFFAOYSA-N NC=1N=C2N(C(C=1C=O)=O)C=CC=C2C Chemical compound NC=1N=C2N(C(C=1C=O)=O)C=CC=C2C CHVBUQHMBCYXDS-UHFFFAOYSA-N 0.000 description 1
- BGQUXQDERZQRCF-UHFFFAOYSA-N O1CCCCC1.S1C2=C(C=C1)C=CC=C2 Chemical compound O1CCCCC1.S1C2=C(C=C1)C=CC=C2 BGQUXQDERZQRCF-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241001147397 Ostrinia Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000005724 cycloalkenylene group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- OVYTZAASVAZITK-UHFFFAOYSA-M sodium;ethanol;hydroxide Chemical compound [OH-].[Na+].CCO OVYTZAASVAZITK-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- FPCFCMNSACXKRQ-UHFFFAOYSA-N spiro[1,3-dioxane-2,3'-1h-indole]-2'-one Chemical compound O=C1NC2=CC=CC=C2C11OCCCO1 FPCFCMNSACXKRQ-UHFFFAOYSA-N 0.000 description 1
- PRMHWSVVQZVDGR-UHFFFAOYSA-N spiro[1,3-dioxolane-2,3'-1h-indole]-2'-one Chemical compound O=C1NC2=CC=CC=C2C11OCCO1 PRMHWSVVQZVDGR-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Environmental Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种芳香稠环二酮类化合物及其制备方法与应用,化合物具有如式I所示的结构式。与现有技术相比,本发明中的芳香稠环二酮类化合物具有几丁质酶(如玉米螟几丁质酶OfChi‑h、秀丽隐杆线虫几丁质酶CeCht1和人壳三糖几丁质酶HsChit1等)抑制活性,通过对其抑制效果、选择性进行评价研究可知,该芳香稠环二酮类化合物对亚洲玉米螟、人类、秀丽隐杆线虫、烟曲霉菌、粘质沙雷氏菌几丁质酶均表现出抑制活性,在生物学和生物化学领域具有广泛的应用场景。
Description
技术领域
本发明属于几丁质酶抑制剂技术领域,涉及一种芳香稠环二酮类化合物及其制备方法与应用。
背景技术
几丁质是昆虫外骨骼和中肠围食膜、线虫卵壳、真菌细胞壁的重要组成部分,在昆虫蜕皮、线虫孵化及蜕皮和真菌生长过程中伴随着几丁质的合成与降解。GH18家族几丁质酶是水解几丁质的关键酶,在细菌营养吸收、真菌细胞壁重塑、线虫卵化、昆虫蜕皮中发挥着不可或缺的作用。抑制昆虫或线虫蜕皮相关的几丁质酶,会导致昆虫或线虫蜕皮失败而死亡,因此几丁质酶被认为是开发农药的重要靶点。
人体表达两种几丁质酶和多种类几丁质酶蛋白,其中HsChit1与肺部纤维化有关,临床和药理学研究发现HsChit1可以作为治疗特异性肺纤维化的靶点,而几丁质酶AMCase可作为抗哮喘药物的靶点。近些年,随着生物学和生物化学的发展,玉米螟来源的几丁质酶OfChi-h和OfChtI、线虫几丁质酶CeCht1、人几丁质酶HsChit1和AMCase、粘质沙雷氏菌几丁质酶SmChiA的晶体结构得到解析,为小分子几丁质酶抑制剂的合理设计提供了重要基础。
因此,针对不同靶标开发几丁质酶抑制剂,在农业和医药领域都具有重要的应用前景。
发明内容
本发明的目的是提供一种芳香稠环二酮类化合物及其制备方法与应用。本发明化合物在抑制控制农业害虫、用于特异性肺纤维化、抗真菌感染和抑制细菌生长等方面具有广泛的应用前景。
本发明的目的可以通过以下技术方案来实现:
一种芳香稠环二酮类化合物,该化合物的结构式如式I所示:
其中:
X表示其所在吡啶环上的任意一个或多个位置上的取代基,并且各取代基分别独立地选自下组之一:H、卤素、氰基、硝基、取代或未取代的C1-C6烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C3-C7环烷基、取代或未取代的C5-C7环烯基、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的5元或6元杂环基、取代或未取代的8元至12元杂芳二环环系、ORa、SRa、C(O)Rb、C(O)ORa、NRaRb、S(O)2Ra;优选地,X表示其所在吡啶环上的任意一个或两个位置上的取代基,且各取代基分别独立地选自下组之一:H、甲基、乙基、丙基、环丙基、正丁基、叔丁基、卤素、氰基、硝基、甲氧基;更优选地,X表示其所在吡啶环上的任意一个位置上的取代基,X选自下组之一:H、甲基、乙基、丙基、环丙基、正丁基、叔丁基、卤素。
M为单键,或具有1-10个碳原子的取代或未取代的亚烷基,所述的亚烷基为直链或支链的亚烷基;优选地,M为单键,或具有1-5个碳原子的取代或未取代的亚烷基。
Y选自下组之一:H、卤素、氰基、硝基、取代或未取代的C1-C6烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C3-C7环烷基、取代或未取代的C5-C7环烯基、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的5元或6元杂环基、取代或未取代的8元至12元杂芳二环环系、ORa、SRa、C(O)Rb、C(O)ORa、NRaRb、S(O)2Ra;优选地,Y选自下组之一:卤素、氰基、硝基、取代或未取代的C1-C6烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C3-C7环烷基、取代或未取代的C5-C7环烯基、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的吲哚基、取代或未取代的吗啉环、取代或未取代的哌嗪环、取代或未取代的5元或6元杂环基、取代或未取代的8元至12元杂芳二环环系。
进一步地,Ra、Rb分别独立地选自下组之一:H、取代或未取代的C1-C6烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C3-C7环烷基、取代或未取代的C5-C7环烯基、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的5元或6元杂环基、取代或未取代的8元至12元杂芳二环环系。
进一步地,X、M、Y、Ra、Rb中,所述的取代是指被下组的一个或多个基团取代:卤素、氰基、硝基、R'、OR'、Si(R')3、NR'R"、C(O)R'、C(O)OR'、C(O)NR'R"、SR'、S(O)mR1、S(O)2NR'R"、OC(O)R1、OC(O)NR'R"、OS(O)2R1、OS(O)2NR'R"、N(R2)C(O)R1、N(R2)C(O)NR'R"、N(R2)S(O)2R1、N(R2)S(O)2NR'R";优选地,X、M、Y中,所述的取代是指被下组的一个或多个基团取代:卤素、氰基、硝基、氨基、甲氧基、甲硫基、C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6卤代烯基、C2-C6炔基、C2-C6卤代炔基。m为1或2。
进一步地,R'、R"分别独立地选自下组之一:H、C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6卤代烯基、C2-C6炔基、C2-C6卤代炔基、取代或未取代的C3-C7环烷基、取代或未取代的C5-C7环烯基、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的C3-C7环烷基、取代或未取代的3元至6元杂环基、取代或未取代的8元至12元杂芳二环环系;
R1选自下组之一:C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6卤代烯基、C2-C6炔基、C2-C6卤代炔基、取代或未取代的C3-C7环烷基、取代或未取代的C5-C7环烯基、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的5元或6元杂环基、取代或未取代的8元至12元杂芳二环环系;
R2选自下组之一:H、C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6卤代烯基、C2-C6炔基、C2-C6卤代炔基、取代或未取代的C3-C7环烷基、取代或未取代的C5-C7环烯基、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的5元或6元杂环基、取代或未取代的8元至12元杂芳二环环系。
进一步地,R'、R"、R1、R2中,所述的取代是指被下组的一个或多个基团取代:卤素、氰基、硝基、C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6卤代烯基、C2-C6炔基、C2-C6卤代炔基、羟基、羟基C1-C4烷基、OR3、NR3R4、C(O)R3、C(O)OR3、C(O)NR3R4、SR3、S(O)mR5、S(O)2NR3R4、OC(O)R5、OC(O)NR3R4、OS(O)2R5、OS(O)2NR3R4、N(R6)C(O)R5、N(R6)C(O)NR3R4、N(R6)S(O)2R5、N(R6)S(O)2NR3R4;m为1或2。
进一步地,R3、R4、R6分别独立地选自下组之一:H、C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6卤代烯基、C2-C6炔基、C2-C6卤代炔基、C1-C6烷基氧基;
R5选自下组之一:C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6卤代烯基、C2-C6炔基、C2-C6卤代炔基。
一种芳香稠环二酮类化合物的制备方法,该方法包括以下步骤:
1)式A化合物与丙二酸二乙酯反应,得到式B化合物;
2)式B化合物与三氯氧磷反应,得到式C化合物;
3)式C化合物与氨水反应,得到式D化合物;
4)式E化合物与氰乙酸甲酯反应,得到式F化合物;
5)式D化合物与式F化合物反应,得到式G化合物;
6)式G化合物与N,N-二甲基甲酰胺二甲基缩醛反应,即得到所述的芳香稠环二酮类化合物;
所述的式A化合物、式B化合物、式C化合物、式D化合物、式E化合物、式F化合物、式G化合物的结构式分别为:
一种芳香稠环二酮类化合物在制备几丁质酶抑制剂中的应用。该芳香稠环二酮类化合物也可用于预防和治疗以几丁质酶为靶点的疾病,用于特异性肺纤维化、哮喘、抗真菌感染和抑制细菌生长等,用于控制鳞翅目害虫生长和线虫卵孵化。尤其是用于抑制18家族几丁质酶活性,该化合物在抑制剂18家族几丁质酶活性中使用的终浓度不低于10μM。
一种芳香稠环二酮类衍生物,基于所述的芳香稠环二酮类化合物,所述的衍生物为式I化合物的光学异构体、顺反异构体、药学上可接受的盐或溶剂合物。
一种几丁质酶抑制剂,基于所述的芳香稠环二酮类化合物,所述的抑制剂包括式I化合物、式I化合物的光学异构体、式I化合物的顺反异构体、式I化合物药学上可接受的盐、式I化合物的溶剂合物中的一种或更多种。
本发明中的芳香稠环二酮类化合物,具有刚性的平面结构和多个氢键受体及供体,其刚性平面结构能够与几丁质酶结合口袋中暴露于溶液的芳香基氨基酸残基发生π-π堆积作用,其氢键受体(如羰基氧原子)和氢键供体能够与结合口袋里的氨基酸产生直接或者水介导的氢键作用,从而产生对几丁质酶的抑制效果。
与现有技术相比,本发明具有以下特点:
1)本发明中的芳香稠环二酮类化合物具有几丁质酶(如玉米螟几丁质酶OfChi-h、秀丽隐杆线虫几丁质酶CeCht1和人壳三糖几丁质酶HsChit1等)抑制活性,通过对其抑制效果、选择性进行评价研究可知,该芳香稠环二酮类化合物对亚洲玉米螟、人类、秀丽隐杆线虫、烟曲霉菌、粘质沙雷氏菌几丁质酶均表现出抑制活性,在生物学和生物化学领域具有广泛的应用场景。
2)通过抑制剂的抑制活性所获得的数据,包括抑制百分数、抑制常数测定,结果表明该类结构表现出了广泛的抑制活性,对OfChi-h、OfChtI、CeCht1、HsChit1、AmCase、AfChiB1和SmChiA都表现出一定的抑制活性。
3)特别地对应表中的化合物I-2对OfChi-h、CeCht1、HsChit1和SmChiA抑制率都在90%以上,且化合物I-2对亚洲玉米螟几丁质酶OfChi-h的Ki为58nM,对人HsChit1的Ki为295nM,对粘质沙雷氏菌SmChiA的Ki为126nM。
附图说明
图1为I-2对亚洲玉米螟几丁质酶OfChi-h的抑制活性测试图;
图2为I-2对人壳三糖几丁质酶HsChit1的抑制活性测试图;
图3为I-2对粘质沙雷氏菌几丁质酶的抑制活性测试图;
图4为I-28对亚洲玉米螟几丁质酶OfChi-h的抑制活性测试图。
具体实施方式
除非另有定义,本发明所用的技术和科学上的术语,与本发明所属领域的通用技术的一般理解具有相同的意义。
术语“C1-C6烷基”指具有1-6个碳原子的直链或支链烷基,例如甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基、叔丁基、或类似基团。
术语“C2-C6烯基”指具有2-6个碳原子的直链或支链的烯基,例如乙烯基、烯丙基、1-丙烯基、异丙烯基、1-丁烯基、2-丁烯基、或类似基团。
术语“C2-C6炔基”指具有2-6个碳原子的直链或支链的炔基,例如乙炔基、丙炔基、或类似基团。
术语“C3-C7环烷基”指具有3-7个碳原子的环状烷基,例如环丙基、环丁基、环戊基、环己基、环庚基、或类似基团。
术语“C5-C7环烯基”指具有5-7个碳原子的、具有一个或多个双键的环状烯基,例如环戊烯基、环己烯基、环庚烯基、1,3-环己二烯基、1,4-环己二烯基、或类似基团。
术语“C1-C4烷氧基”指具有1-4个碳原子的直链或支链烷氧基,例如甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、仲丁氧基、叔丁氧基、或类似基团。
术语“卤素”指氟、氯、溴、或碘。术语“卤代的”指被相同或不同的一个或多个上述卤原子取代的基团,例如三氟甲基、五氟乙基、七氟异丙基、或类似基团。
术语“环”或“环系”指碳环或杂环。
术语“杂环”指形成所述杂环骨架的原子中至少一个原子不是碳,为氮、氧或硫。通常,杂环包含不超过4个氮、不超过2个氧和/或不超过2个硫。除非另外指明,杂环可以是饱和的、部分不饱和的或完全不饱和的环。在本发明的一个优选的实施方式中,所述杂环中包含1-4个独立选自N、S、和O的杂原子。
术语“环系”指两个或更多个环并在一起的稠环。
术语“5元或6元杂环基”指含一个或多个选自氮、氧或硫的杂原子的五元或六元环,例如吡啶基、噻唑基、异噻唑基、噻吩基、呋喃基、吡咯基、吡唑基、嘧啶基、四氢呋喃基、4,5-二氢噻唑-2-基、2-氰基亚胺基-4-氧-1,3-噻唑烷-3-基、2-氰基亚胺基-4-氧-1,3-噻嗪烷-3-基、噁唑基、异噁唑基、1H-四唑基、1H-1,2,3-***基、4H-1,2,4-***基、1,2,3-噻二唑基、1,2,4-噻二唑基、1,3,4-噻二唑基、1,2,4-噁二唑基、1,2,5-噁二唑基、1,3,4-噁二唑基或四唑基等。
术语“杂环环系”指环系中的至少一个环是杂环的环系。
术语“杂芳环环系”指环系中的至少一个环为芳族环的体系。
术语“8元至12元杂芳二环环系”或“8元至14元杂芳二环或三环环系”可选自下组:苯并呋喃、苯并[b]噻吩、吲哚、喹啉、异喹啉、1H-吲唑、1H-苯并[d]咪唑、苯并[d]噻唑、苯并[d]噁唑、苯并[d]异噁唑、苯并[d][1,2,3]噻二唑、2,3-二氢咪唑并[1,2-a]吡啶、喹唑啉、喹喔啉、噌啉、酞嗪、1,8-萘啶、4,5,6,7-四氢苯并[b]噻吩、苯并[b]噻吩-1,1-二氧烷、8H-茚并[2,1-b]噻吩、7,8-二氢-6H-环戊[4,5]噻吩并[2,3-d]嘧啶、3,5,6,7-四氢-4H-环戊[4,5]噻吩并[2,3-d]嘧啶-4-酮、螺[吲哚啉-3,2'-[1,3]二氧戊环]-2-酮、螺[吲哚啉-3,2'-[1,3]二氧六环]-2-酮、或吲哚啉-2,3-二酮等。
术语“烷基”是指烷烃分子中少掉一个氢原子而成的基团;术语“亚烷基”是指烷烃分子中少掉两个氢原子而成的基团。类似地,“亚烯基”、“亚炔基”、“亚环烷基”、“亚环烯基”、“亚苯基”、“亚萘基”、“亚杂环基”或“亚杂芳二环或三环环系”的定义类似。
本发明所述的基团除非特别说明是“取代或未取代的”,否则本发明的基团均可被选自下组的取代基所取代:卤素、氰基、硝基、C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6卤代烯基、C2-C6炔基、C2-C6卤代炔基、羟基、羟基C1-C4烷基、OR3、NR3R4、C(O)R3、C(O)OR3、C(O)NR3R4、SR3、S(O)mR5、S(O)2NR3R4、OC(O)R5、OC(O)NR3R4、OS(O)2R5、OS(O)2NR3R4、N(R6)C(O)R5、N(R6)C(O)NR3R4、N(R6)S(O)2R5或N(R6)S(O)2NR3R4等,其中,所述的R3、R4、R5、R6的定义同前,m为1或2。
惰性溶剂指的是不与原料发生反应的各种溶剂,包括各种直链、支链或环状的醇、醚或酮、卤代烷、1,4-二氧六环、乙腈、四氢呋喃、N,N-二甲基甲酰胺(DMF)、二甲基亚砜(DMSO)等。
本发明的化合物可以含有一个或多个不对称中心,并因此以消旋体、外消旋混合物、单一对映体、非对映异构体化合物和单一非对映体的形式出现。可以存在的不对称中心,取决于分子上各种取代基的性质。每个这种不对称中心将独立地产生两个旋光异构体,并且所有可能的旋光异构体和非对映体混合物和纯或部分纯的化合物包括在本发明的范围之内。本发明包括化合物的所有异构形式。
药物组合物和施用方法:
本发明的式I化合物可用于药物组合物中,药物组合物包含安全有效量范围内的本发明式I化合物、抗生素或其药理上可接受的盐及药理上可以接受的赋形剂或载体。其中“安全有效量”指的是:化合物的量足以明显改善病情,而不至于产生严重的副作用。通常,药物组合物含有1-2000mg本发明化合物/剂,更佳地,含有5-200mg本发明化合物/剂。较佳地,所述的“一剂”为一个胶囊或药片。
“药学上可以接受的载体”指的是:一种或多种相容性固体或液体填料或凝胶物质,它们适合于人使用,而且必须有足够的纯度和足够低的毒性。“相容性”在此指的是组合物中各组份能和本发明的化合物以及它们之间相互掺和,而不明显降低化合物的药效。药学上可以接受的载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如)、润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
本发明化合物或药物组合物的施用方式没有特别限制,代表性的施用方式包括(但并不限于):口服、直肠、肠胃外(静脉内、肌肉内或皮下)、和局部给药。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型中,活性化合物与至少一种常规惰性赋形剂(或载体)混合,如柠檬酸钠或磷酸二钙,或与下述成分混合:(a)填料或增容剂,例如,淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸;(b)粘合剂,例如,羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和***胶;(c)保湿剂,例如,甘油;(d)崩解剂,例如,琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐、和碳酸钠;(e)缓溶剂,例如石蜡;(f)吸收加速剂,例如,季胺化合物;(g)润湿剂,例如鲸蜡醇和单硬脂酸甘油酯;(h)吸附剂,例如,高岭土;和(i)润滑剂,例如,滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠,或其混合物。胶囊剂、片剂和丸剂中,剂型也可包含缓冲剂。
固体剂型如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备,如肠衣和其它本领域公知的材料。它们可包含不透明剂,并且,这种组合物中活性化合物或化合物的释放可以延迟的方式在消化道内的某一部分中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。必要时,活性化合物也可与上述赋形剂中的一种或多种形成微胶囊形式。
用于口服给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外,液体剂型可包含本领域中常规采用的惰性稀释剂,如水或其它溶剂,增溶剂和乳化剂,例知,乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油,特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外,组合物也可包含助剂,如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性化合物外,悬浮液可包含悬浮剂,例如,乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液,和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
用于局部给药的本发明化合物的剂型包括软膏剂、散剂、贴剂、喷射剂和吸入剂。活性成分在无菌条件下与生理上可接受的载体及任何防腐剂、缓冲剂,或必要时可能需要的推进剂一起混合。
本发明化合物可以单独包装,或者与多肽类抗生素以及其他药学上可接受的化合物联合包装。
使用药物组合物时,是将安全有效量的药物组合物适用于需要治疗的哺乳动物(如人),其中施用时剂量为药学上认为的有效给药剂量,对于60kg体重的人而言,日给药剂量通常为1-2000mg,优选5-500mg。当然,具体剂量还应考虑给药途径、病人健康状况等因素,这些都是熟练医师技能范围之内的。
下面结合附图和具体实施例对本发明进行详细说明。本实施例以本发明技术方案为前提进行实施,给出了详细的实施方式和具体的操作过程,但本发明的保护范围不限于下述的实施例。
实施例:
采用以下方法制备芳香稠环二酮类化合物,
步骤一:式A化合物在无溶剂或在惰性溶剂中,与丙二酸二乙酯在110-130℃反应,反应结束后,抽滤所得到固体,使用乙醇洗涤滤饼,真空干燥得到式B化合物;
步骤二:冰浴条件下,向盛有20mL N,N-二甲基甲酰胺(DMF)的圆底烧瓶中加入三氯氧磷(POCl3)(30mmol),在冰浴条件下,搅拌40min后,将10mmol的式B化合物溶解在20mlDMF中,然后缓慢加入烧瓶中,加料完毕后升温至80℃反应1h,TLC跟踪反应结束,反应液温度降至室温后,倒入冰水中,搅拌30min后,抽滤并用水洗涤后,置于红外烘箱中烘干,得到式C化合物;
步骤三:称取式C化合物10mmol于100mL圆底烧瓶中,加入20ml乙醇,3mL氨水(25%-28%),70℃搅拌反应2h,TLC跟踪反应至完成。将反应液冷却至室温,抽滤得到黄色粗产物,无水乙醇洗涤滤饼,柱层析(AcOEt:PE=1:1)分离得到式D化合物;
步骤四:将氰乙酸甲酯(1.0-1.2equiv.)加入到相应的胺(式E化合物)中(1.0equiv.),室温搅拌。经过0.5-12h,有白色固体析出,抽滤得到固体产物,滤饼使用冷却的***洗涤,烘干得到白色固体产物,部分反应未析出固体化合物,柱层析可得式F化合物,产率72%-93%;
步骤五:式D化合物和式F化合物在惰性溶剂中,加入10%的碱,在70℃搅拌反应10min-2h,有大量固体析出,TLC跟踪反应完成后,冷却至室温,抽滤得到固体,并用冷的乙醇洗涤滤饼,然后在红外烘箱中烘干得到式G化合物;
步骤六:称取式G化合物1mmol,加入到5mL DMFDMA中,反应10min-1h,析出大量固体,TLC跟踪反应结束,冷却至室温,加入2mL乙醇,抽滤得到固体,并用乙醇洗涤滤饼,然后在红外烘箱中烘干得到式H化合物,即为芳香稠环二酮类化合物。
其中,上述制备方法的工艺条件,例如反应物、溶剂、碱、所用化合物的量、反应温度、反应所需时间等并不限于上面的特例。
下面以化合物I-2的合成为例,简要说明该系列化合物的具体合成。
2-羟基-9-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮的合成:
称取2-氨基-3-甲基吡啶(10.8g,100mmol)、丙二酸二乙酯(16g,100mmol)于250ml圆底烧瓶中,110℃下反应12h,冷却至室温,抽滤得到白色固体,并用冷却的无水乙醇洗涤滤饼,红外烘箱中烘干,得到白色固体16.2g,产率约为91%,产物可直接用于下步反应。1HNMR(400MHz,DMSO-d6)δ2.48(s,3H),5.44(s,1H),7.20(t,J=7.0Hz,1H),7.87(d,J=6.8Hz,1H),8.84(d,J=6.8Hz,1H),11.52(brs,1H)ppm。
2-氯-9-甲基-4-氧代-4H-吡啶并[1,2-a]嘧啶-3-甲醛的合成:
冰浴条件下,向盛有20mL DMF的圆底烧瓶中加入POCl3(30mmol),在冰浴条件下,搅拌40min后,将10mmol的化合物溶解在20ml DMF中,然后缓慢加入烧瓶中,加料完毕后升温至80℃反应1h,TLC跟踪反应结束,反应液温度降至室温后,倒入冰水中,搅拌30min后,抽滤并用水洗涤后,置于红外烘箱中烘干。将烘干的固体用乙醇重结晶得到2-氯-9-甲基-4-氧代-4H-吡啶并[1,2-a]嘧啶-3-甲醛,产率78%,1H NMR(400MHz,DMSO-d6)δ10.24(s,1H),9.04(d,J=6.9Hz,1H),8.24(d,J=7.1Hz,1H),7.58(t,J=7.0Hz,1H),2.53(s,3H)。
2-氨基-9-甲基-4-氧代-4H-吡啶并[1,2-a]嘧啶-3-甲醛的合成:
称取2-氯-9-甲基-4-氧代-4H-吡啶并[1,2-a]嘧啶-3-甲醛(2.223g,10mmol)于100mL圆底烧瓶中,加入20ml乙醇、3mL氨水(25%-28%),70℃搅拌反应2h,TLC跟踪反应至完成。将反应液冷却至室温,抽滤得到黄色粗产物,无水乙醇洗涤滤饼,柱层析(AcOEt:PE=1:1)分离得到白色固体产物,即为2-氨基-9-甲基-4-氧代-4H-吡啶并[1,2-a]嘧啶-3-甲醛,产率为42%,1H NMR(400MHz,Chloroform-d)δ10.32(s,1H),9.13(s,1H),8.80(d,J=7.1Hz,1H),7.59(d,J=6.8Hz,1H),6.87(t,J=7.0Hz,1H),5.74(s,1H),2.43(s,3H)ppm。
2-氰基-N-(吡啶-3-基甲基)乙酰胺的合成:
称取3-氨甲基吡啶1.08g、氰乙酸甲酯1.2g,室温下反应4小时,TLC跟踪反应结束,所得液体浓缩得到PE:EA=2:1柱层析得到白色固体,产率81.2%,1H NMR(400MHz,CDCl3)δ8.54–8.46(m,2H),7.66(dt,J=7.8,1.9Hz,1H),7.29-7.26(m,2H),4.47(d,J=5.9Hz,2H),3.43(s,2H)ppm。
2-氨基-N-(3-吡啶基甲基)-10-甲基-5-氧代-5H-吡啶并[1,2-a:2',3'-d]嘧啶-3-甲酰胺的合成:
称取2-氨基-9-甲基-4-氧代-4H-吡啶并[1,2-a]嘧啶-3-甲醛203mg和2-氰基-N-(吡啶-3-基甲基)乙酰胺175mg置于50mL的圆底烧瓶中,加入10mL10%NaOH乙醇溶液,反应20min,析出大量固体,冷却至室温后,抽滤并使用乙醇洗涤,烘干得到2-氨基-N-(3-吡啶基甲基)-10-甲基-5-氧代-5H-吡啶并[1,2-a:2',3'-d]嘧啶-3-甲酰胺,产率:78.6%,淡黄色固体,1H NMR(400MHz,DMSO-d6)δ=9.49(t,J=5.8Hz,1H),8.86(s,1H),8.68(d,J=6.8Hz,1H),8.64–8.56(d,J=1.6Hz 1H),8.48(dd,J=4.8,1.6Hz,1H),8.00(s,2H),7.77(d,J=7.8Hz,1H),7.69(d,J=6.8Hz,1H),7.39(dd,J=7.6,4.8Hz,1H),6.99(t,J=7.0Hz,1H),4.50(d,J=5.6Hz,2H),2.45(s,3H)ppm.
化合物I-2的合成:
称取2-氨基-N-(3-吡啶基甲基)-10-甲基-5-氧代-5H-吡啶并[1,2-a:2',3'-d]嘧啶-3-甲酰胺360mg,加入到5mL N,N-二甲基甲酰胺二甲基缩醛(DMFDMA)中,110℃下反应10min,有大量固体析出,冷却至室温后,加入2mL乙醇,抽滤并另外使用2mL乙醇洗涤,得到化合物I-2,黄绿色固体,产率67.3%,1H NMR(400MHz,DMSO-d6)δ9.56(t,J=5.8Hz,1H),8.93(s,1H),8.74(d,J=7.1Hz,1H),8.64(s,1H),8.53(d,J=3.8Hz,1H),7.88(d,J=7.9Hz,1H),7.78(d,J=6.7Hz,1H),7.48(dd,J=7.8,4.9Hz,1H),7.08(t,J=7.0Hz,1H),4.52(d,J=5.7Hz,2H),2.47(s,3H)ppm。
其他化合物可以通过类似的方法,使用相应的原料,按照合成反应通式合成,核磁数据列于下表。
表1芳香稠环二酮类化合物结构及其核磁
实施例中所用到的酶OfChi-h、OfChtI、CeCht1、HsChit1、AmCase、AfChiB1、SmChiA参考下述参考文献:
Liu,T.,Chen,L.,Zhou,Y.,Jiang,X.,Duan,Y.,&Yang,Q.(2017).Structure,catalysis,and inhibition of OfChi-h,the lepidoptera-exclusive insectchitinase.Journal of Biological Chemistry,292(6),2080-2088.
Chen,L.,Zhou,Y.,Qu,M.,Zhao,Y.,&Yang,Q.(2014).Fully deacetylatedchitooligosaccharides act as efficient glycoside hydrolase family 18chitinaseinhibitors.Journal of Biological Chemistry,289(25),17932-17940.
Chen,Q.,Chen,W.,Kumar,A.,Jiang,X.,Janezic,M.,Zhang,K.Y.,&Yang,Q.(2021).Crystal Structure and Structure-Based Discovery of Inhibitors of theNematode Chitinase Ce Cht1.Journal of Agricultural and Food Chemistry,69(11),3519-3526.
Schüttelkopf,A.W.,Andersen,O.A.,Rao,F.V.,Allwood,M.,Rush,C.L.,Eggleston,I.M.,&van Aalten,D.M.(2011).Bisdionin C A Rationally Designed,Submicromolar Inhibitor of Family 18Chitinases.ACS medicinal chemistryletters,2(6),428-432.
抑制率测试方法:
将待测化合物溶解在二甲基亚砜(DMSO)中,配制成10mM母液。
反应体系:总体积100μL的反应体系中含有适量的几丁质酶、20μM MU-(GlcNAc)2、2%(v/v)DMSO、10mM NaH2PO4、10mM Na2HPO4(pH 6.0)和不同浓度的抑制剂。
在30℃条件下,首先将待测几丁质酶和相应的化合物孵育10min,然后加入底物MU-(GlcNAc)2,继续反应20min后,加入100μL的0.5M的碳酸钠溶液终止反应,通过酶标仪(Tecan Infinite 200Pro)测定荧光强度,激发波长360nm,发射波长440nm。实验组荧光强度记做FE,不含底物的阴性对照组荧光强度记做FN,不含化合物的阳性对照组荧光强度记做FP,空白对照荧光强度记做FB,通过如下公式计算抑制活性。
抑制率=[1-(FE-FN)/(FP-FB)]×100%
抑制常数Ki值的测定:
在三个不同的底物浓度下,测定不同浓度化合物的抑制活性,以反应速率的倒数为纵坐标,化合物浓度为横坐标,通过Dixon plots法计算化合物的Ki值。
表2芳香稠环二酮类化合物对不同几丁质酶在10μM浓度下的抑制活性
图1为I-2对亚洲玉米螟几丁质酶OfChi-h的抑制活性测试图,图1显示I-2对亚洲玉米螟几丁质酶OfChi-h的Ki为58nM。
图2为I-2对人壳三糖几丁质酶HsChit1的抑制活性测试图,图2显示I-2对人壳三糖几丁质酶HsChit1的Ki为295nM。
图3为I-2对粘质沙雷氏菌几丁质酶的抑制活性测试图,图3显示I-2对粘质沙雷氏菌几丁质酶的Ki为126nM。
图4为I-28对亚洲玉米螟几丁质酶OfChi-h的抑制活性测试图,图4显示I-28对亚洲玉米螟几丁质酶OfChi-h的Ki为65nM。
上述的对实施例的描述是为便于该技术领域的普通技术人员能理解和使用发明。熟悉本领域技术的人员显然可以容易地对这些实施例做出各种修改,并把在此说明的一般原理应用到其他实施例中而不必经过创造性的劳动。因此,本发明不限于上述实施例,本领域技术人员根据本发明的揭示,不脱离本发明范畴所做出的改进和修改都应该在本发明的保护范围之内。
Claims (10)
1.一种芳香稠环二酮类化合物,其特征在于,该化合物的结构式如式I所示:
其中:
X表示其所在吡啶环上的任意一个或多个位置上的取代基,并且各取代基分别独立地选自下组之一:H、卤素、氰基、硝基、取代或未取代的C1-C6烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C3-C7环烷基、取代或未取代的C5-C7环烯基、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的5元或6元杂环基、取代或未取代的8元至12元杂芳二环环系、ORa、SRa、C(O)Rb、C(O)ORa、NRaRb、S(O)2Ra;
M为单键,或具有1-10个碳原子的取代或未取代的亚烷基,所述的亚烷基为直链或支链的亚烷基;
Y选自下组之一:H、卤素、氰基、硝基、取代或未取代的C1-C6烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C3-C7环烷基、取代或未取代的C5-C7环烯基、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的5元或6元杂环基、取代或未取代的8元至12元杂芳二环环系、ORa、SRa、C(O)Rb、C(O)ORa、NRaRb、S(O)2Ra。
2.根据权利要求1所述的一种芳香稠环二酮类化合物,其特征在于,Ra、Rb分别独立地选自下组之一:H、取代或未取代的C1-C6烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C3-C7环烷基、取代或未取代的C5-C7环烯基、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的5元或6元杂环基、取代或未取代的8元至12元杂芳二环环系。
3.根据权利要求2所述的一种芳香稠环二酮类化合物,其特征在于,X、M、Y、Ra、Rb中,所述的取代是指被下组的一个或多个基团取代:卤素、氰基、硝基、R'、OR'、Si(R')3、NR'R"、C(O)R'、C(O)OR'、C(O)NR'R"、SR'、S(O)mR1、S(O)2NR'R"、OC(O)R1、OC(O)NR'R"、OS(O)2R1、OS(O)2NR'R"、N(R2)C(O)R1、N(R2)C(O)NR'R"、N(R2)S(O)2R1、N(R2)S(O)2NR'R";m为1或2。
4.根据权利要求3所述的一种芳香稠环二酮类化合物,其特征在于,
R'、R"分别独立地选自下组之一:H、C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6卤代烯基、C2-C6炔基、C2-C6卤代炔基、取代或未取代的C3-C7环烷基、取代或未取代的C5-C7环烯基、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的C3-C7环烷基、取代或未取代的3元至6元杂环基、取代或未取代的8元至12元杂芳二环环系;
R1选自下组之一:C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6卤代烯基、C2-C6炔基、C2-C6卤代炔基、取代或未取代的C3-C7环烷基、取代或未取代的C5-C7环烯基、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的5元或6元杂环基、取代或未取代的8元至12元杂芳二环环系;
R2选自下组之一:H、C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6卤代烯基、C2-C6炔基、C2-C6卤代炔基、取代或未取代的C3-C7环烷基、取代或未取代的C5-C7环烯基、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的5元或6元杂环基、取代或未取代的8元至12元杂芳二环环系。
5.根据权利要求4所述的一种芳香稠环二酮类化合物,其特征在于,R'、R"、R1、R2中,所述的取代是指被下组的一个或多个基团取代:卤素、氰基、硝基、C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6卤代烯基、C2-C6炔基、C2-C6卤代炔基、羟基、羟基C1-C4烷基、OR3、NR3R4、C(O)R3、C(O)OR3、C(O)NR3R4、SR3、S(O)mR5、S(O)2NR3R4、OC(O)R5、OC(O)NR3R4、OS(O)2R5、OS(O)2NR3R4、N(R6)C(O)R5、N(R6)C(O)NR3R4、N(R6)S(O)2R5、N(R6)S(O)2NR3R4;m为1或2。
6.根据权利要求5所述的一种芳香稠环二酮类化合物,其特征在于,
R3、R4、R6分别独立地选自下组之一:H、C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6卤代烯基、C2-C6炔基、C2-C6卤代炔基、C1-C6烷基氧基;
R5选自下组之一:C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6卤代烯基、C2-C6炔基、C2-C6卤代炔基。
8.一种如权利要求1至6任一项所述的芳香稠环二酮类化合物在制备几丁质酶抑制剂中的应用。
9.一种芳香稠环二酮类衍生物,基于如权利要求1至6任一项所述的芳香稠环二酮类化合物,其特征在于,所述的衍生物为式I化合物的光学异构体、顺反异构体、药学上可接受的盐或溶剂合物。
10.一种几丁质酶抑制剂,基于如权利要求1至6任一项所述的芳香稠环二酮类化合物,其特征在于,所述的抑制剂包括式I化合物、式I化合物的光学异构体、式I化合物的顺反异构体、式I化合物药学上可接受的盐、式I化合物的溶剂合物中的一种或更多种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111472410.2A CN114105986A (zh) | 2021-12-06 | 2021-12-06 | 一种芳香稠环二酮类化合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111472410.2A CN114105986A (zh) | 2021-12-06 | 2021-12-06 | 一种芳香稠环二酮类化合物及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114105986A true CN114105986A (zh) | 2022-03-01 |
Family
ID=80366998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111472410.2A Pending CN114105986A (zh) | 2021-12-06 | 2021-12-06 | 一种芳香稠环二酮类化合物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114105986A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08277203A (ja) * | 1995-04-06 | 1996-10-22 | Kaiyo Bio Technol Kenkyusho:Kk | キチナーゼ阻害物質 |
CN1474651A (zh) * | 2000-09-19 | 2004-02-11 | 核黄素和黄素衍生物作为几丁质酶抑制剂的用途 | |
US20090215798A1 (en) * | 2005-06-21 | 2009-08-27 | University Court Of The University Of Dundee | Inhibitor Compounds |
CN105829285A (zh) * | 2013-10-23 | 2016-08-03 | 中外制药株式会社 | 喹唑啉酮和异喹啉酮衍生物 |
CN106700087A (zh) * | 2016-12-05 | 2017-05-24 | 江汉大学 | 一种三重氢键超分子聚合物及其制备方法 |
CN108467395A (zh) * | 2018-05-09 | 2018-08-31 | 大连理工大学 | 一种几丁质酶抑制剂及其应用 |
-
2021
- 2021-12-06 CN CN202111472410.2A patent/CN114105986A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08277203A (ja) * | 1995-04-06 | 1996-10-22 | Kaiyo Bio Technol Kenkyusho:Kk | キチナーゼ阻害物質 |
CN1474651A (zh) * | 2000-09-19 | 2004-02-11 | 核黄素和黄素衍生物作为几丁质酶抑制剂的用途 | |
US20090215798A1 (en) * | 2005-06-21 | 2009-08-27 | University Court Of The University Of Dundee | Inhibitor Compounds |
CN105829285A (zh) * | 2013-10-23 | 2016-08-03 | 中外制药株式会社 | 喹唑啉酮和异喹啉酮衍生物 |
CN106700087A (zh) * | 2016-12-05 | 2017-05-24 | 江汉大学 | 一种三重氢键超分子聚合物及其制备方法 |
CN108467395A (zh) * | 2018-05-09 | 2018-08-31 | 大连理工大学 | 一种几丁质酶抑制剂及其应用 |
Non-Patent Citations (3)
Title |
---|
KAN WANG等: "Cyanoacetamides (IV): Versatile One-Pot Route to 2-Quinoline-3-carboxamides", 《ACS COMB. SCI.》, vol. 14, no. 5, 9 April 2012 (2012-04-09), pages 316 - 322, XP093112824, DOI: 10.1021/co3000133 * |
NADA A. NOURELDIN等: "Design, synthesis and biological evaluation of novel quinazoline-2, 4-diones conjugated with different amino acids as potential chitin synthase inhibitors", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, vol. 152, 4 May 2018 (2018-05-04), pages 560 - 569 * |
PENGTAO YUAN等: "X-ray Structure and Molecular Docking Guided Discovery of Novel Chitinase Inhibitors with a Scaffold of Dipyridopyrimidine-3-carboxamide", 《J. AGRIC. FOOD CHEM.》, vol. 68, no. 47, 5 November 2020 (2020-11-05), pages 13584 - 13593 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109678796B (zh) | Pd-1/pd-l1小分子抑制剂及其制备方法和用途 | |
CN108524482B (zh) | 2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途 | |
KR20100081294A (ko) | 간염과 같은 바이러스성 감염 치료용 이미다조[1,2-a] 피라진 화합물 | |
CN113061138B (zh) | 一种三氮唑[5,4-d]嘧啶酮三环类化合物及制备方法和用途 | |
Tam et al. | Nucleosides. 112. Synthesis of some new pyrazolo [1, 5-a]-1, 3, 5-triazines and their C-nucleosides | |
CN111393404B (zh) | 一类苯并噻吩类化合物及其药物组合物及应用 | |
Hadady et al. | C-(β-D-Glucopyranosyl) heterocycles as potential glycogen phosphorylase inhibitors | |
CN109134463B (zh) | β-咔啉类5型磷酸二酯酶抑制剂及其制备方法和用途 | |
CN108003155A (zh) | 抗菌的高哌啶基取代的3,4二氢-1h[1,8]萘啶酮类 | |
MXPA06001645A (es) | Isotiazoloquinolonas y compuestos relacionados como agentes anti-infecciosos. | |
US20110135603A1 (en) | Inhibitors of phosphatidylinositol 3-kinase | |
FI93444C (fi) | Menetelmä terapeuttisesti aktiivisten dihydropyridiinijohdannaisten valmistamiseksi | |
SU893134A3 (ru) | Способ получени имидазо-2,1-8-тиазолин-или-тиазин-производных в виде смеси или отдельных изомеров или их кислотно-аддитивных солей | |
HU189648B (en) | Process for producing imidazo/1,2-a/pyridine derivatives and pharmaceutical compositions containing them | |
AU2010216219A1 (en) | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase | |
EP3992184A1 (en) | Hydrazone amide derivatives and use thereof in preparation of anti-osteoporosis drugs | |
CN104725393A (zh) | 一种岩白菜素的衍生物、制备方法及应用 | |
CN109503496A (zh) | 丙酮酸脱氢酶系抑制剂类化合物及其制备方法和应用 | |
CN114105986A (zh) | 一种芳香稠环二酮类化合物及其制备方法与应用 | |
CN103450178A (zh) | 一类香豆素接枝噻唑腙类衍生物及其制备方法 | |
CN101781295B (zh) | 5-氨基-1,2,4-噻二唑类化合物及其制备方法 | |
CN115135646A (zh) | 取代的多环化合物及其药物组合物和用途 | |
CN102241665B (zh) | 4-(4,5-二甲氧羰基-1,3-二硫戊环-2-基)苯甲酰-l-氨基酸苄酯及其合成方法和应用 | |
CN104098524A (zh) | 1-间甲氧基苯甲酰基-3-苯基-1,4-二氢-1,2,4,5-四嗪及制备和应用 | |
CN113387934B (zh) | 一种多芳基取代咪唑衍生物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |